La promotion médicale
par de fausses revues médicales
Neuf revues fantôme ont été publiées entre 2000 et 2005 par une filiale australienne d’Elsevier appelée Excerpta Medica. En plus de l’Australasian Journal of Bone and Joint Medicine, il s’agit de: The Australasian Journal of Bone and Joint Medicine, the Australasian Journal of Neurology, the Australasian Journal of Hospital Medicine, the Australasian Journal of General Practice, the Australasian Journal of Cardiology, the Australasian Journal of Cardiovascular Medicine, the Australasian Journal of Clinical Pharmacy, the Australasian Journal of Clinical Practice et the Australasian Journal of Musculoskeletal Medicine.
Treize autres allaient sortir pour désinformer les généralistes dans plusieurs spécialités
[Lire] (pharmacritique.20minutes-blogs)
Merck et Elsevier ont édité une fausse revue médicale: outil marketing pour Fosamax et Vioxx. Ghost management révélé lors du procès Vioxx
[Lire] (pharmacritique.20minutes-blogs)
Plus d'infos (www.the-scientist.com)
- Elsevier tweaks custom pub rules
Publishing company Elsevier is revising its policies and procedures for partnering with pharmaceutical companies to create custom publications in response to recent media attention over a fake journal, called the Australasian Journal of Bone and Joint Medicine (AJBJM), created by the company and paid for by Merck.
http://www.the-scientist.com/blog/display/55750/
- Elsevier published 6 fake journals
Scientific publishing giant Elsevier put out a total of six publications between 2000 and 2005 that were sponsored by unnamed pharmaceutical companies and looked like peer reviewed medical journals, but did not disclose sponsorship, the company has admitted.
http://www.the-scientist.com/blog/display/55679/
- Merck published fake journal
Merck paid an undisclosed sum to Elsevier to produce several volumes of a publication that had the look of a peer-reviewed medical journal, but contained only reprinted or summarized articles--most of which presented data favorable to Merck products--that appeared to act solely as marketing tools with no disclosure of company sponsorship
http://www.the-scientist.com/blog/display/55671/
 | . |
 |
